Literature DB >> 31382209

Optical/MRI dual-modality imaging of M1 macrophage polarization in atherosclerotic plaque with MARCO-targeted upconversion luminescence probe.

Yabin Wang1, Yan Zhang2, Zhao Wang3, Jibin Zhang3, Rui Rui Qiao4, Mengqi Xu3, Ning Yang3, Lei Gao3, Hongyu Qiao5, Mingyuan Gao6, Feng Cao7.   

Abstract

Pro-inflammatory M1 macrophage is identified as a prominent component initializing the progress of vulnerable atherosclerotic plaque. Here, we constructed anti-MARCO NaGdF4:Yb,Er@NaGdF4 upconversion nanoparticles (UCNPs) by conjugating polyclonal MARCO antibody to the surface of NaGdF4:Yb,Er@NaGdF4via condensation reaction. UCNPs displayed highly mono-dispersion with average sizes of 26.7 ± 0.8 nm and favorable biocompatibility. In vivo upconversion optical imaging revealed that distinctive fluorescence signal could be observed in the regions of carotid artery 10 min post-injection, reached peak value at 1 h and decreased back to baseline at 24 h post-injection. The carotid artery wall demonstrated high signal intensity on T1-weighted MR images after anti-MARCO UCNPs injection, as determined by 7.0T MRI. Immunofluorescence staining of tissue section of carotid artery revealed that MARCO was highly abundant in shoulder regions of plaque. Anti-MARCO UCNPs is a promising optical/MRI dual-modality imaging probe which can non-invasively reflect M1 phenotype macrophages behavior in vivo.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  M1 macrophage polarization; Multimodality molecular imaging; Upconversion nanoprobe; Vulnerable atherosclerotic plaque

Year:  2019        PMID: 31382209     DOI: 10.1016/j.biomaterials.2019.119378

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  8 in total

1.  Dual-modality Imaging of Angiogenesis in Unstable Atherosclerotic Plaques with VEGFR2-Targeted Upconversion Nanoprobes in vivo.

Authors:  Yan Fang; Ruichen Yang; Yi Hou; Yabin Wang; Ning Yang; Mengqi Xu; Sulei Li; Shan Gao; Min Jiang; Jingyang Fan; Yazhuo Hu; Zhenzhen Xu; Lei Gao; Feng Cao
Journal:  Mol Imaging Biol       Date:  2022-05-23       Impact factor: 3.484

Review 2.  Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis.

Authors:  Jun Chen; Xixi Zhang; Reid Millican; Jennifer Sherwood; Sean Martin; Hanjoong Jo; Young-Sup Yoon; Brigitta C Brott; Ho-Wook Jun
Journal:  Adv Drug Deliv Rev       Date:  2021-01-09       Impact factor: 15.470

Review 3.  Nanotechnology for cardiovascular diseases.

Authors:  Qinqin Hu; Zheyan Fang; Junbo Ge; Hua Li
Journal:  Innovation (Camb)       Date:  2022-02-02

Review 4.  Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis.

Authors:  Wei Chen; Maaike Schilperoort; Yihai Cao; Jinjun Shi; Ira Tabas; Wei Tao
Journal:  Nat Rev Cardiol       Date:  2021-11-10       Impact factor: 49.421

Review 5.  Current advances in the imaging of atherosclerotic vulnerable plaque using nanoparticles.

Authors:  Ming Zhang; Zhongjian Xie; Haijiao Long; Kun Ren; Lianjie Hou; Yu Wang; Xiaodan Xu; Weixing Lei; Zhicheng Yang; Shakeel Ahmed; Han Zhang; Guojun Zhao
Journal:  Mater Today Bio       Date:  2022-03-07

6.  Osteopontin-Targeted and PPARδ-Agonist-Loaded Nanoparticles Efficiently Reduce Atherosclerosis in Apolipoprotein E-/- Mice.

Authors:  Xu Huang; Yang Zhang; Weiwei Zhang; Cheng Qin; Yan Zhu; Yan Fang; Yabin Wang; Chengchun Tang; Feng Cao
Journal:  ACS Omega       Date:  2022-08-15

Review 7.  Macrophage Polarization States in the Tumor Microenvironment.

Authors:  Ava J Boutilier; Sherine F Elsawa
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 6.208

8.  Ciprofloxacin promotes polarization of CD86+CD206‑ macrophages to suppress liver cancer.

Authors:  Mengtian Fan; Sicheng Chen; Yaguang Weng; Xian Li; Yingjiu Jiang; Xiaowen Wang; Mengjun Bie; Liqin An; Menghao Zhang; Bin Chen; Gaigai Huang; Jinghong Wu; Mengying Zhu; Qiong Shi
Journal:  Oncol Rep       Date:  2020-04-29       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.